Swedish Company BioLamina to Enable Next-Generation Cell Therapies for Serious Chronic Diseases

BioLamina, the leading primary cell culture system on the market, led by Klaus Langhoff-Roos and the team, has received a €20 million EIB commitment to expand its development of laminin technologies, enabling next-generation cell therapies and more advanced, animal-free methods for drug safety testing. Cell therapies can be used to target conditions such as type 1 diabetes, Parkinson’s disease, heart failure, acute liver failure, and cancer. Many of these conditions remain difficult to treat or have no cure.

BioLamina will use the EIB commitment to scale production of its laminins, specialized proteins that support the growth and maintenance of cells in laboratory environments. These proteins enable consistent, high-quality cell production for applications such as cell therapies and drug testing, and are used by researchers, biotech firms, and pharmaceutical companies globally.

Backed by the InvestEU programme, the funding will support manufacturing optimization, product expansion, and technological development, strengthening both the company’s growth and the European Union’s position in life sciences and regenerative medicine.

The investment reflects a broader goal of translating Europe’s scientific excellence into globally competitive companies. Supporting BioLamina’s growth is aimed at scaling life sciences innovation within Europe, creating jobs, strengthening competitiveness, and advancing public health outcomes.

The EIB loan is structured as venture debt, a form of long-term financing for innovative, high-growth companies. It complements venture capital and equity funding while limiting dilution for existing shareholders, helping extend runway and support scaling operations.

The rapid transition of cell therapies from research to clinical use highlights the challenge of scaling high-quality cell production. This financing supports the expansion of technology and manufacturing capabilities at a critical stage of industry growth.

The operation supports the InvestEU objective of advancing research, development, and innovation across Europe. It also aligns with the EIB Group’s TechEU programme and broader EU initiatives such as BioTechEU, aimed at strengthening Europe’s competitiveness in biotechnology and life sciences.